Compare DTM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTM | ROIV |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | DTM | ROIV |
|---|---|---|
| Price | $119.88 | $22.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $124.91 | $24.31 |
| AVG Volume (30 Days) | 636.8K | ★ 6.9M |
| Earning Date | 02-25-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $1,175,000,000.00 | $20,329,000.00 |
| Revenue This Year | $27.83 | N/A |
| Revenue Next Year | $8.45 | $741.42 |
| P/E Ratio | $30.42 | ★ N/A |
| Revenue Growth | ★ 20.39 | N/A |
| 52 Week Low | $83.30 | $8.73 |
| 52 Week High | $122.70 | $23.91 |
| Indicator | DTM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 57.80 |
| Support Level | $116.82 | $21.57 |
| Resistance Level | $119.62 | $23.91 |
| Average True Range (ATR) | 2.47 | 0.73 |
| MACD | -0.26 | 0.08 |
| Stochastic Oscillator | 66.21 | 66.28 |
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.